BCAB Stock Overview
A clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
BioAtla, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.69 |
| 52 Week High | US$4.02 |
| 52 Week Low | US$0.67 |
| Beta | 0.94 |
| 1 Month Change | -55.90% |
| 3 Month Change | -58.30% |
| 1 Year Change | -68.96% |
| 3 Year Change | -96.55% |
| 5 Year Change | n/a |
| Change since IPO | -97.77% |
Recent News & Updates
Recent updates
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
Oct 08We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate
Jul 16
BioAtla: A Buried ADC Concern Gets Some New Life In 2024
May 02Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?
Mar 14Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?
Nov 05We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully
Jun 27Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?
Mar 24BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans
Sep 27BioAtla: Back From The Dead
Sep 23BioAtla: Promising Signal In NSCLC, But Concerns Remain
Aug 23BioAtla reports Q2 results
Aug 09We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate
May 11Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth
Jan 06BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans
Jul 24Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?
Mar 16Shareholder Returns
| BCAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -52.3% | -3.6% | -2.4% |
| 1Y | -69.0% | -2.6% | 23.4% |
Return vs Industry: BCAB underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: BCAB underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| BCAB volatility | |
|---|---|
| BCAB Average Weekly Movement | 17.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BCAB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BCAB's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 65 | Jay Short | www.bioatla.com |
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types.
BioAtla, Inc. Fundamentals Summary
| BCAB fundamental statistics | |
|---|---|
| Market cap | US$33.47m |
| Earnings (TTM) | -US$81.82m |
| Revenue (TTM) | US$11.00m |
3.0x
P/S Ratio-0.4x
P/E RatioIs BCAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCAB income statement (TTM) | |
|---|---|
| Revenue | US$11.00m |
| Cost of Revenue | US$74.12m |
| Gross Profit | -US$63.12m |
| Other Expenses | US$18.70m |
| Earnings | -US$81.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.69 |
| Gross Margin | -573.81% |
| Net Profit Margin | -743.79% |
| Debt/Equity Ratio | 0% |
How did BCAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 11:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioAtla, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Justin Zelin | BTIG |
| Tiago Fauth | Credit Suisse |